Self-administered questionnaire survey to determine the presence or absence of joint pain during bevacizumab treatment for lung, ovarian, colorectal cancers.

The principal end-point is the frequency of arthralgia after 6 months of treatment with Bevacizumab.

Inclusion Criteria:

• Patient with ovarian, colorectal or lung cancer receiving bevacizumab therapy
• Male or female (aged ≥18 years old)
• Performance Status (PS) between 0 and 2
• Expected life> 3 months
• Ability to answer a self-questionnaire
• Obtaining the non-opposition of patient participation

Exclusion Criteria:

• Pregnant or lactating woman
• Rapid evolution of neoplastic pathology
• Major cognitive disorders that do not allow filling of the self-questionnaire
• Impossibility to submit to medical monitoring for social, psychological or geographical reasons
• Patients under guardianship or curatorship

Patients treated with Bevacizumab for Lung, ovarian or colorectal cancers.